Get the Stockscreener App
1.28
0.78%
-0.01
Lava Therapeutics Nv stock is traded at $1.28, with a volume of 55,380.
It is down -0.78% in the last 24 hours and up +28.00% over the past month.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
See More
Previous Close:
$1.29
Open:
$1.31
24h Volume:
55,380
Relative Volume:
0.13
Market Cap:
$34.19M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-0.6667
EPS:
-1.92
Net Cash Flow:
$5.89M
1W Performance:
+36.17%
1M Performance:
+28.00%
6M Performance:
-18.47%
1Y Performance:
-41.82%
1-Day Range:
$1.26
$1.3152
1-Week Range:
$1.13
$1.465
52-Week Range:
$0.8502
$4.21
Lava Therapeutics Nv Stock (LVTX) Company Profile
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.28 | 34.19M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.74 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.74 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.51 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.14 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Canada
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com
Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria
Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India
JMP Securities Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
LAVA Therapeutics stock hits 52-week low at $1.35 - Investing.com
Lava Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
LAVA Reports Third Quarter 2024 Financial Results and - GlobeNewswire
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - The Manila Times
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 5.6% – Time to Sell? - Defense World
Some Major Key Players In The RNA Editing Market: - InsightAce Analytic
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
ACAD: 3 Healthcare Stocks Analysts Expect to Rally Over 50% - StockNews.com
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive - Simply Wall St
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint - Yahoo Finance
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):